Wolff–Parkinson–White (WPW) Syndrome
A guide to WPW ECG findings, supraventricular tachycardia, risk assessment and accessory-pathway ablation.
Wolff–Parkinson–White syndrome occurs when an accessory electrical pathway connects the atria and ventricles and is associated with tachyarrhythmia. The ECG may show pre-excitation with a short PR interval and delta wave, but pre-excitation can be intermittent.
Assessment
Symptoms may include sudden regular palpitations, dizziness or fainting. ECG, rhythm documentation and sometimes exercise or ambulatory monitoring help assess the pathway. Electrophysiology study can define how rapidly the accessory pathway conducts and whether it participates in AVRT. Risk assessment is especially important when atrial fibrillation occurs with rapid pre-excited conduction.
Treatment
Catheter ablation can provide definitive treatment by eliminating the accessory pathway and is considered for symptomatic patients and selected higher-risk asymptomatic individuals. Acute treatment of a wide or irregular pre-excited tachycardia differs from routine AV-node blocking therapy and requires urgent expert care.
Fainting, severe symptoms or a very rapid irregular rhythm requires emergency assessment.
Clinical Depth and Risk Assessment
Risk is not defined by the diagnostic label alone. Symptoms, ECG and rhythm findings, ventricular function, myocardial scar or structural change, family history, associated disease and previous events are integrated. Genetic results, when relevant, require expert interpretation; a variant of uncertain significance is not equivalent to a diagnosis.
Diagnostic Strategy and Limitations
Testing is selected to answer a specific question. ECG, ambulatory monitoring, echocardiography, cardiac MRI, CT, laboratory testing, exercise assessment or invasive evaluation have complementary roles. A normal test may not exclude an intermittent disorder, while an abnormal measurement must be checked against technical quality and clinical probability.
Treatment Decision Framework
Treatment may combine risk-factor control, condition-specific medicines, rhythm or heart-failure therapy, catheter procedures, surgery and implanted devices. These options address different mechanisms and are not automatically substitutes for one another. Expected benefit, uncertainty, procedural burden and the patient’s informed preferences should be discussed explicitly.
Long-Term Follow-up
Follow-up assesses symptoms, exercise capacity, rhythm burden, ventricular function and treatment tolerance over time. Family screening may be appropriate in inherited or suspected inherited disease. New fainting, sustained rapid rhythm, chest pain, neurological symptoms or rapidly worsening breathlessness requires urgent assessment.
Questions to Discuss With the Cardiology Team
- Which finding has the greatest influence on my present risk?
- Which test or treatment would genuinely change management?
- What symptoms should lead to an earlier appointment or emergency care?
- Do relatives need clinical or genetic assessment?
Medical Information Note
This page supports an informed discussion with the clinical team. It does not provide a personal diagnosis, medicine dose or sports-clearance decision.